Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Kidney (renal cell) cancer
Trial Type:  Treatment
Results 1-25 of 117 for your search:
Start Over
A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374)
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CA209-374, NCI-2016-00405, 2015-003286-28, NCT02596035
Everolimus in Treating Patients with Kidney Cancer Who Have Undergone Surgery
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0931, NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer Who Have No Evidence of Disease after Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: E2810, NCI-2012-00723, CDR0000730383, ECOG-E2810, NCT01575548
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29637, NCI-2015-01390, 2014-004684-20, NCT02420821
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AV-951-15-303, NCI-2016-00282, NCT02627963
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B9991003, NCI-2016-00392, 2015-002429-20, JAVELIN RENAL 101, NCT02684006
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Stereotactic Radiosurgery in Treating Patients With Kidney Tumors Who are Poor Candidates for Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 12806, NCI-2010-01064, NCT00458484
Entinostat in Combination with Aldesleukin in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 145208, NCI-2012-02900, CDR0000662915, NCI 7870, NCT01043159, 7870, NCT01038778
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
Hydroxychloroquine and Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IIT11PLK01, NCI-2012-00427, 11-080, 1302010628, NCT01550367
Pazopanib Hydrochloride and Bevacizumab in Treating Patients with Previously Untreated Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 191711, NCI-2012-01247, 13-069, NCT01684397
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients with Pancreatic Neuroendocrine Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 andover
Trial IDs: 201303150, NCI-2013-00641, NCT01784861
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105RC101, NCI-2013-01264, NCT01806064
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RX-0201-P2-A-09, NCI-2014-02443, NCT02089334
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-04, NCI-2015-00740, NCT02386111
Ixazomib Citrate and Peginterferon Alfa-2b in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GU-071, NCI-2015-01878, ERP GU-071, NCT02447887
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
Vandetanib and Metformin Hydrochloride in Treating Patients with Advanced Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0157, NCI-2015-01978, P152144, NCT02495103
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-06, NCI-2015-02086, NCT02543645
Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMBG453X2101, NCI-2015-02091, 2015-002354-12, NCT02608268
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: E7080-A001-111, NCI-2016-00529, NCT02501096
Start Over